Detalhe da pesquisa
1.
Accelerating Clinical Development of Idasanutlin through a Physiologically Based Pharmacokinetic Modeling Risk Assessment for CYP450 Isoenzyme-Related Drug-Drug Interactions.
Drug Metab Dispos
; 50(3): 214-223, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34937801
2.
Addressing Today's Absorption, Distribution, Metabolism, and Excretion (ADME) Challenges in the Translation of In Vitro ADME Characteristics to Humans: A Case Study of the SMN2 mRNA Splicing Modifier Risdiplam.
Drug Metab Dispos
; 50(1): 65-75, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34620695
3.
Investigating the effect of autoinduction in cynomolgus monkeys of a novel anticancer MDM2 antagonist, idasanutlin, and relevance to humans.
Xenobiotica
; 46(8): 667-76, 2016 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-26586447
4.
A UGT2B10 splicing polymorphism common in african populations may greatly increase drug exposure.
J Pharmacol Exp Ther
; 352(2): 358-67, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25503386
5.
Separation of fast from slow anabolism by site-specific PEGylation of insulin-like growth factor I (IGF-I).
J Biol Chem
; 286(22): 19501-10, 2011 Jun 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-21460230
6.
Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, BRAF-mutated Urothelial Carcinoma.
Mol Cancer Ther
; 20(11): 2177-2188, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34433660
7.
Dose-proportional pharmacokinetics of d-threo-methylphenidate after a repeated-action release dosage form.
J Clin Pharmacol
; 47(1): 64-9, 2007 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-17192503
8.
Specific Correction of Alternative Survival Motor Neuron 2 Splicing by Small Molecules: Discovery of a Potential Novel Medicine To Treat Spinal Muscular Atrophy.
J Med Chem
; 59(13): 6086-100, 2016 07 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-27299419
9.
Epitope characterization of the ADA response directed against a targeted immunocytokine.
J Pharm Biomed Anal
; 114: 296-304, 2015 Oct 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-26093509
10.
Pharmacokinetics of meloxicam in patients with juvenile rheumatoid arthritis.
J Clin Pharmacol
; 44(8): 866-72, 2004 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-15286090
11.
Pharmacokinetics, metabolism and distribution of PEGs and PEGylated proteins: quo vadis?
Drug Discov Today
; 19(10): 1623-31, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-24929223
12.
Pharmacological control of platelet-leukocyte interactions by the human anti-P-selectin antibody inclacumab--preclinical and clinical studies.
Thromb Res
; 131(5): 401-10, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23522853
13.
Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects.
Science
; 325(5939): 490-3, 2009 Jul 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-19541954
14.
High response rate in the phase I/II study of meloxicam in juvenile rheumatoid arthritis.
J Rheumatol
; 29(5): 1079-83, 2002 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-12022326